About
NeXtGen™ Biologics, Inc. is a medical device company that specializes in advanced biotechnology for regeneration and scar-free healing. The company has developed a portfolio of patents for its extracellular matrix (ECM) platform technology, which is derived from the axolotl, a salamander known for its remarkable regenerative abilities. NeXtGen uses this technology to create solutions for various medical conditions across specialties such as wound care, general surgery, trauma, plastic surgery, cardiovascular diseases, neurosurgery, orthopedics, and ophthalmology. The flagship product, NeoMatriX® Wound Matrix, is made from the dermal ECM of the axolotl. It is available in sheets of different sizes, designed to optimize the wound environment and promote healing for various wound types, including partial and full-thickness wounds and pressure ulcers. NeoMatriX is notable for being a room-temperature product that is readily available off-the-shelf, making it easy to use and cost-effective. NeXtGen is focused on expanding its infrastructure and increasing awareness of its products among healthcare professionals following FDA clearance for NeoMatriX in the United States.
Technologies
Keywords
Company Information
-
Employees 20
-
Founded 2014
-
Total Funding $2390500
Location
Tech City Cir, Alachua, Florida, United States, 32615
